Zydus receives final approval for Etodolac ER Tablets

30 Jan 2014 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drugs Administration (USFDA) to market Etodolac Extended-release Tablets USP, 400 mg, 500 mg, and 600 mg. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis. The group now has 88 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

911.50 10.20 (1.13%)
31-Dec-2025 11:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.85
Dr. Reddys Lab 1266.25
Cipla 1498.35
Zydus Lifesciences 911.50
Lupin 2096.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×